RxDoctor Payments Data

Erin Holleman

Psychiatric/Mental Health · Malvern, ARNPI 1801021696

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 49 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$536
  • Axsome Therapeutics, Inc.$472
  • Otsuka America Pharmaceutical, Inc.$104
  • Lundbeck LLC$63
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55
  • Teva Pharmaceuticals USA, Inc.$15

What the payments were for

  • Food & beverage$1,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 55th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$20,882
Medicare patients
20
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl82$98,190
AuvelityDextromethorphan Hbr/Bupropion42$51,148
AristadaAripiprazole Lauroxil14$45,053
Lurasidone Hcl11$5,034
Duloxetine Hcl51$668
Venlafaxine Hcl ErVenlafaxine Hcl24$607
Gabapentin24$483
Quetiapine Fumarate ErQuetiapine Fumarate12$380
Prazosin Hcl11$344
Fluoxetine Hcl36$336
Clonazepam49$332
Eszopiclone15$249
Trazodone Hcl47$232
Bupropion XlBupropion Hcl20$226
Diazepam17$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$536$98,19082 claims
Axsome Therapeutics, Inc.Auvelity$472$51,14842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Malvern

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →